Pre-exposure prophylaxis: Exploring suitable HIV prevention strategies for China

VernacularTitle:暴露前预防：探索适合中国的HIV预防策略
Author: An LIU ¹ ; Xi WANG ; Jiangzhu YE ; Lijun SUN
Author Information

1. 首都医科大学附属北京佑安医院感染中心门诊，北京　100069
Keywords: HIV; Pre-exposure prophylaxis; Tenofovir disoproxil fumarate; Tenofovir alafenamide
From: Chinese Journal of Epidemiology 2021;42(2):357-363
CountryChina
Language:Chinese
Abstract: Pre-exposure prophylaxis (PrEP) is one of the main methods recommended by international guidelines for preventing HIV infection, and increasing attention has been paid to it in China. In 2019, emtricitabine/tenofovir alafenamide (F/TAF) was approved by the US FDA as the second PrEP option besides emtricitabine/tenofovir disoproxil fumarate (F/TDF). This article reviews the latest international guideline recommendations on PrEP, and the relevant clinical study data, discusses the considerations and challenges in implementing PrEP in the context of clinical practice in China, and provides suggestions for improving the awareness, accessibility, affordability and adherence of PrEP.